Clinical application of belimumab in lupus nephritis
As a human monoclonal antibody specific for B lymphocyte stimulator （BLyS）， belimumab has recently become the first drug approved by the US Food and Drug Administration （FDA） for managing adult active lupus nephritis （LN）. LN affects up to 60% of patients with systemic lupus erythematosus （SLE） and...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Chinês |
| Vydáno: |
Editorial Department of Journal of Clinical Nephrology
2022-10-01
|
| Edice: | Linchuang shenzangbing zazhi |
| Témata: | |
| On-line přístup: | http://www.lcszb.com/thesisDetails#10.3969/j.issn.1671-2390.2022.10.011 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|